Journal Information
Vol. 9. Issue 5.
Pages 435-461 (September - October 2003)
Share
Share
Download PDF
More article options
Vol. 9. Issue 5.
Pages 435-461 (September - October 2003)
RECOMENDAÇÕES/GUIDELINES
DOI: 10.1016/S0873-2159(15)30691-7
Open Access
Recomendações de abordagem diagnóstica e terapêutica da pneumonia da comunidade em adultos imunocompetentes
Portuguese Respiratory Society guidelines for the management of community – acquired pneumonia in immunocompetent adults
Visits
...
Article information
RESUMO

A Sociedade Portuguesa de Pneumologia apresenta um conjunto de recomendações que pretendem traduzir para o nosso país o “estado da arte” em relação à abordagem diagnóstica, terapêutica e preventiva da pneumonia adquirida na comunidade no adulto imunocompetente. Estas propostas devem ser entendidas como linhas de orientação geral, não devendo substituir o senso clínico, aplicado à resolução de cada caso individual.

Constituiu objectivo prioritário uma estratificação dos doentes de acordo com o risco de morbilidade e mortalidade, de modo a fundamentar mais racionalmente as seguintes decisões: escolha do local de tratamento(ambulatório ou internamento hospitalar), exames complementares a realizar e terapêutica antimicrobiana a adoptar. São igualmente enunciadas um conjunto de recomendações relativas à prevenção da PAC.

Os autores propõem a realização de estudos multicêntricos prospectivos, idealmente em colaboração com outras sociedades científicas, tendo em vista uma melhor caracterização da realidade nacional e a revisão periódica do presente documento.

REV PORT PNEUMOL 2003; IX(5): 435-461

Palavras-chave:
Pneumonia adquirida na comunidade
diagnóstico
terapêutica
prevenção
recomendações
ABSTRACT

The Portuguese Respiratory Society makes a series of recommendations as to the state of the art of the diagnostic, therapeutic and preventive approach to community-acquired pneumonia in immunocompetent adults in Portugal. These proposals should be regarded as general guidelines and are not intended to replace the clinical sense used in resolving each individual case.

Our main goal is to stratify the patients according to the risk of morbidity and mortality in order to justify the following decisions more rationally: the choice of place of treatment (outpatient or inpatient), diagnostic tests and antimicrobial therapy. We also make a set of recommendations for the prevention of CAP.

We plan to conduct multi-centre prospective studies, preferably in collaboration with other scientific societies, in order to be able to characterise the situation in Portugal more accurately and regularly update this document.

REV PORT PNEUMOL 2003; IX(5): 435-461

Key-words:
Community-acquired pneumonia
diagnostic
therapeutic
prevention
guidelines
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
J.T. Macfarlane, T. Boswell, G. Douglas, R. Finch, et al.
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
Thorax, 56 (2001), pp. iv1-iv64
[2.]
F. Froes, R. Vicência.
Pneumonia da Comunidade em Portugal Continental – Internamentos Hospitalares em 1997.
Revista Portuguesa Pneumologia, 5 (1999), pp. 477-485
[3.]
F. Froes.
Pneumonia da Comunidade no Adulto em Portugal Continental – Incidência e Mortalidade dos Internamentos Hospitalares nos anos de 1998 a 2000.
Revista Portuguesa Pneumologia, 3 (2003), pp. 187-194
[4.]
American Thoracic Society.
Guidelines for the management of adults with community-acquired pneumonia.
Am J Respir Crit Care Med, 163 (2001), pp. 1730-1754
[5.]
B.J. Martson, J.F. Plouffe, T.M. File, et al.
Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Study Group.
Arch Intern Med, 157 (1997), pp. 1709-1718
[6.]
J. Almirall, I. Morato, F. Riera, et al.
Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study.
Eur Respir J, 6 (1993), pp. 14-18
[7.]
M.J. Fine, M.A. Smith, C.A. Carson, et al.
Prognosis and outcomes of patients with community-acquired pneumonia.
JAMA, 275 (1996), pp. 134-141
[8.]
A. Carneiro, J.A. Paiva, A. Sarmento, P. Amaro, E. Silva, H. Estrada.
Pneumonia grave adquirida na comunidade em cuidados intensivos,
[9.]
J.G. Bartlett, S.F. Dowell, L.A. Mandell, T.M. File, D.M. Musher, M.J. Fine.
Practice guidelines for the management of community-acquired pneumonia in adults.
Clin Infect Dis, 31 (2000), pp. 383-421
[10.]
R.C. Finch, M.A. Woodhead.
Practical considerations and guidelines for the management of community-acquired pneumonia.
Drugs, 55 (1998), pp. 31-45
[11.]
D. Lieberman, F. Schlaeffer, I. Boldur, et al.
Multiple pathogens in adult admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients.
Thorax, 51 (1996), pp. 179-184
[12.]
British Thoracic Society Research Committee And The Public Health Laboratory Service.
The aetiology, management and outcome of severe community-acquired pneumonia in the intensive care unit.
Respir Med, 86 (1992), pp. 7-13
[13.]
Ers Taskforce Report.
Guidelines for management of adult community-acquired lower respiratory tract infections.
Eur Respir J, 11 (1998), pp. 986-991
[14.]
J. Melo Cristino.
Dados apresentados em reunião de trabalho da Sociedade Portuguesa de Pneumologia, (2002),
[15.]
National Committee For Clinical Laboratory Standards.
Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard M7-A5.
National Committee for Clinical Laboratory Standards, (2000),
[16.]
J.D. Heffelfinger, S.F. Dowel, J.H. Jorgensen, et al.
Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drugresistant Streptococcus pneumoniae Therapeutic Working Group.
Arch Intern Med, 160 (2000), pp. 1399-1408
[17.]
J.F. Plouffe, R.F. Breiman, R.R. Facklam.
Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention.
JAMA, 275 (1996), pp. 194-198
[18.]
D.R. Feikin, A. Schuchat, M. Kolczak, et al.
Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance.
Am J Public Health, 90 (2000), pp. 223-229
[19.]
B.J. Marston, H.B. Lipman, R.F. Breiman.
Surveillance for legionaires’ disease: risk factors for morbidity and mortality.
Arch Intern Med, 154 (1994), pp. 2417-2422
[20.]
J.E. Stout, V.L. Yu.
Legionellosis.
N Engl J Med, 337 (1997), pp. 682-687
[21.]
T.J. Marrie.
Pneumonia in the elderly.
Curr Opin Pulm Med, 2 (1996), pp. 192-197
[22.]
M.J. Fine, T.E. Auble, D.M. Yealy, et al.
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med, 336 (1997), pp. 243-250
[23.]
W.S. Lim, J.T. Macfarlane, T.C. Boswell, et al.
SCAPA: Study of Community Acquired Pneumonia Aetiology in adults admitted to hospital: implications for management guidelines.
Thorax, 56 (2001), pp. 296-301
[24.]
R.P. Smith, B.J. Lipworth, I.A. Cree, et al.
C-reactive protein. A clinical marker in community-acquired pneumonia.
Chest, 108 (1995), pp. 1288-1291
[25.]
A. Ortqvist, J. Hedlund, B. Wretlind, et al.
Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia.
Scand J Infect Dis, 27 (1995), pp. 457-462
[26.]
O. Leroy, C. Santre, C. Beuscart, et al.
A fiveyear study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit.
Intensive Care Med, 21 (1995), pp. 24-31
[27.]
J.P. Janssens, L. Gauthey, F. Herrmann, et al.
Community-acquired pneumonia in older patients.
J Am Geratr Soc, 44 (1996), pp. 539-544
[28.]
R. Riquelme, A. Torres, M. Al-Ebiary, et al.
Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors.
Am J Respir Crit Care Med, 154 (1996), pp. 1450-1455
[29.]
E. Halm, A. Terstein.
Management of community-acquired pneumonia.
N Engl J Med, 347 (2002), pp. 2039-2045
[30.]
T.P. Meehan, M.J. Fine, H.M. Krumholz, et al.
Quality of care, process and outcomes in elderly patients with pneumonia.
JAMA, 278 (1997), pp. 2080-2084
[31.]
A. Torres, J. Serra-Batlles, A. Ferrer, et al.
Severe community-acquired pneumonia. Epidemiology and prognosis factors.
Am Rev Respir Dis, 114 (1991), pp. 312-318
[32.]
O. Leroy, H. Georges, C. Beuscart, et al.
Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score.
Intensive Care Med, 22 (1996), pp. 1307-1314
[33.]
M. Ruiz, S. Ewig, A. Torres, et al.
Severe communityacquired pneumonia: risk factors and follow-up epidemiology.
Am J Respir Crit Care Med, 160 (1999), pp. 923-929
[34.]
O. Leroy, C. Vandenbussche, C. Coffinier, et al.
Community-acquired aspiration pneumonia in intensive care units: epidemiological and prognosis data.
Am J Respir Crit Care Med, 156 (1997), pp. 1922-1929
[35.]
A. El-Solh, P. Sikka, F. Ramadan, et al.
Etiology of severe pneumonia in the very elderly.
Am J Respir Crit Care Med, 163 (2001), pp. 645-651
[36.]
E. Berntsson, T. Lagergard, O. Strannegard, et al.
Etiology of community-acquired pneumonia in outpatients.
Eur J Clin Microbiol, 5 (1986), pp. 446-447
[37.]
M.A. Woodhead, J.T. McFarlane, J.S. McCracken, et al.
Prospective study of the etiology and outcome of pneumonia in the community.
Lancet, i (1987), pp. 671-674
[38.]
J. Blanquer, R. Blanquer, R. Borras, et al.
Aetio logy of community-acquired pneumonia in Valencia, Spain: a multicentre prospective study.
Thorax, 46 (1991), pp. 508-511
[39.]
G.H. Cassel, J. Drnec, K.B. Waites, et al.
Efficacy of clarythromycin against Mycoplasma pneumoniae.
J Antimicrob Chemother, 27 (1991), pp. 47-59
[40.]
H. Melbye, B.P. Berdal, B. Straume, et al.
Pneumonia: a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice.
Scand J Infect Dis, 24 (1992), pp. 647-655
[41.]
G. Michetti, C. Pugliese, M. Bamberga, et al.
Community-acquired pneumonia: is there difference in etiology between hospitalised and out-patients?.
Minerva Medica, 86 (1995), pp. 341-351
[42.]
T.J. Marie, R.W. Peeling, M.J. Fine, et al.
Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course.
Am J Med, 101 (1996), pp. 508-515
[43.]
J. Almirall, I. Bolibar, J. Vidal, et al.
Epidemiology of community-acquired pneumonia in adults: a population-based study.
Eur Respir J, 15 (2000), pp. 757-763
[44.]
F.J.A. Gutiérrez, D.C. Otero, A.G. Fernadez, et al.
Prospective study of 221 community-acquired pneumonias followed up in an outpatient clinic.
Etiology and clinical-radiologic progression. Med Clin, 116 (2001), pp. 161-166
[45.]
P.Y. Bochud, F. Moser, P. Erard, et al.
Communityacquired pneumonia. A prospective outpatient study.
Medecine (Baltimore), 80 (2001), pp. 75-87
[46.]
J.H. Williams.
Fluoroquinolones for Respiratory Infections – Too valuable to overuse.
Chest, 120 (2001), pp. 1771-1775
[47.]
P.L. Ho, W.S. Tse, K.W. Tsang, et al.
Risk factors for ac-quisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.
Clin Infect Dis, 32 (2001), pp. S9-S15
[48.]
N.O. Fishman, B. Suh, L.M. Veigel, et al.
Three levofloxacin treatment failures of pneumococcal respiratory tract isolates,
[49.]
R. Davidson, R. Cavalvanti, J.L. Brunton, et al.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
NEJM, 346 (2002), pp. 747-750
[50.]
G. Hoffken.
Epidemiology of respiratory tract infections.
Eur Resp J, 10 (2000), pp. 149-155
[51.]
M.T. Kauppinen, E. Herva, et al.
The etiology of community-acquired pneumonia among hospitalised patients during a Chlamydia pneumoniae epidemic in Finland.
J Infect Dis, 172 (1995), pp. 1330-1335
[52.]
L.M. Mundy, P.G. Awarter, D. Oldach, et al.
Community-acquired pneumonia: impact of immune status.
Am J Respir Crit Care Med, 152 (1995), pp. 1309-1315
[53.]
M.T. Kaupinnen, P. Saiku, P. Kujala, et al.
Clinical picture of Chlamydia pneumoniae requiring hospital treatment: a comparison between chlamydial and pneumococ cal pneumonia.
Thorax, 51 (1996), pp. 185-189
[54.]
P.P. Gleason, T.P. Meehan, J.M. Fine, et al.
Associations between initial antimicrobial therapy and outcomes for hospitalised elderly patients with pneumonia.
Arch Intern Med, 159 (1999), pp. 2562-2572
[55.]
S. Ewig, A. Torres.
Severe community-acquired pneumonia.
Clin Chest Med, 20 (1999), pp. 575-587
[56.]
B.M. Farr, D.L. Kaiser, B.D.W. Harrison, et al.
Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features.
Thorax, 44 (1984), pp. 1031-1035
[57.]
M. Ruiz, S. Ewig, M.A. Marcos, et al.
Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity.
Am J Respir Crit Care Med, 160 (1999), pp. 397-405
[58.]
S.J. Skerrett.
Diagnostic testing for community-acquired pneumonia.
Clin Chest Med, 20 (1999), pp. 531-548
[59.]
A. Torres, J.P. De La Bellacasa, A. Xaubet, et al.
Diagnostic value of quantitative cultures of bronchoalveolar lavage and telescoping plugged catheters in mechanically ventilated patients with bacterial pneumonia.
Am Rev Respir Dis, 140 (1989), pp. 306-310
[60.]
A. Torres, P. Jimenez, J.P. De La Bellacasa, et al.
Diagnostic value of non fluoroscopic percutaneous lung needle aspiration in patients with pneumonia.
Chest, 98 (1990), pp. 840-844
[61.]
M.P. Fink, D.R. Snydman, M.S. Niederman, et al.
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin.
Antimicrob Agents Chemother, 38 (1994), pp. 547-557
[62.]
G.R. Pesola.
The urinary antigen test for the diagnosis of pneumococcal pneumonia.
Chest, 119 (2001), pp. 9-11
[63.]
A.C.C. Guardiola, A.C.V. Rodriguez, S.S. Simon, et al.
Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.
Am J Med, 111 (2001), pp. 367-374
[64.]
J.A. Ramirez.
Switch therapy in adult patients with pneumonia.
Clin Pulm Med, 2 (1995), pp. 327-333
[65.]
J.A. Ramirez, S. Vargas, G.W. Ritter, et al.
Early switch from intravenous to oral antibiotics and early hospital discharge: a perspective observational study of 200 consecutive patients with community-acquired pneumonia.
Arch Intern Med, 159 (1999), pp. 2443-2449
[66.]
G. Brum, F. Froes.
Pneumonias – 25 perguntas frequentes em Pneumologia, Sociedade Portuguesa de Pneumologia, (1999),
[67.]
R. Couch.
Prevention and treatment of influenza.
N Engl J Med, 343 (2000), pp. 1778-1787
[68.]
P.A. Gross, A.W. Hermógenes, H.S. Sacks, J. Lau, R.A. Levandowski.
The efficacy of influenza vaccine in elderly persons: a meta analysis and review of the literature.
Ann Intern Med, 123 (1995), pp. 518-527
[69.]
CIRCULAR INFORMATIVA DA DIRECÇÃO GERAL DE SAÚDE Nº.: 48/DT de 24/09/03. Gripe: Vigilância, Vacinação, Profilaxia e Terapêutica em 2003/2004. http://www.dgsaude.pt.
[70.]
Centers For Disease Control And Prevention.
Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR, 51 (2002), pp. 1-31
[71.]
Centers For Disease Control And Prevention.
Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR, 46 (1997), pp. 1-24
[72.]
A. Kuikka, J. Syrjanen, O.-V. Renkonen, et al.
Pneumococcal bacteriemia during a recent decade.
J Infect, 24 (1992), pp. 157-168
[73.]
B. Afessa, W.L. Greaves, W.R. Frederick.
Pneumococcal bacteriemia in adults: a 14-year experience in an inner-city university hospital.
Clin Infect Dis, 21 (1995), pp. 345-351
[74.]
Research Committee Of The British Tho Racic Society.
Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome.
Q J Med, 62 (1987), pp. 195-220
[75.]
Centers For Disease Control And Preven Tion.
Recommendations of the Immunization Practices Advisory Committee: pneumococcal polysaccharide vaccine.
MMWR, 38 (1989), pp. 73-76
[76.]
DIRECTION GÉNÉRALE DE LA SANTÉ. Avis du Comité Technique des vaccinations et de la section des maladies transmissibles du Conseil Supérieur d’Hygiène Publique de France concernant la vaccination antipneumococcique (séance du 3 et du 18 décembre de 1998). Bulletin Officiel nº. 99/3.
[77.]
A. Örtqvist.
Pneumococcal vaccination: current and future issues.
Eur Resp J, 18 (2001), pp. 184-195
[78.]
B. Christenson, P. Lundbergh, J. Hedlund, A. Örtqvist.
Effects of a large-scale intervention with influenza and a 23-valent pneumococcal vaccines in adult aged 65 years or older: a prospective study.
Lancet, 357 (2001), pp. 1008-1011
[79.]
D.S. Fedson, D.M. Musher.
Pneumococcal vaccine.
Vaccines, 2nd ed., pp. 517-563
Copyright © 2003. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?